Skip to content


  • Erratum
  • Open Access

Erratum to: A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

  • 1,
  • 1,
  • 1,
  • 2,
  • 1 and
  • 1Email author
Journal of Neuroinflammation201613:128

  • Received: 23 May 2016
  • Accepted: 23 May 2016
  • Published:

The original article was published in Journal of Neuroinflammation 2013 10:858


The authors would like to issue an erratum for this article [1] and declare the following competing interests, which we inadvertently failed to include in our original publication. The authors would like to apologise for this omission.


The present study provides an important advance over an earlier report in which almitoylethanolamide alone was used [2], in that the co-ultramicronized almitoylethanolamide/luteolin composite demonstrates improved potency by an approximate order of magnitude.




We wish to thank Prof. Ernesto Reverchon, Department of Industrial Engineering, University of Salerno, Italy, for his expertise regarding the measurement of micronized/ co-ultramicronized PEA particle size and energy. Prof. Reverchon is full professor in Chemical Engineering and is the head of the SCF Research Group operating at the University of Salerno, Italy. In the experiments performed in our article [1] Prof. Reverchon only evaluated, during the studies supported by European grants PON01_02512, the electron microscopy structure of micronized/co-ultramicronized PEA particles. These studies were not sponsored by Epitech group.

Competing interests

Dr. Salvatore Cuzzocrea, researcher on the study team, is co-inventor on patent WO2013121449 A8 (Epitech Group SpA) which deals with compositions and methods for the modulation of amidases capable of hydrolysing Nacylethanolamines useable in the therapy of inflammatory diseases. Moreover, Dr. Cuzzocrea is also a co-inventor with Epitech group on the following patents: 1. EP 2 821 083 2. MI2014 A001495 3. 102015000067344 No other authors declare competing interests.

Ethical approval

The study [1] was approved by the University of Messina Animal Care Review Board: protocol number 8/U-apr 16.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Biological and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres, 98166 Messina, Italy
Pharmaco-Biological Department, University of Messina, Viale Annunziata, 98100 Messina, Italy


  1. Paterniti I, Impellizzeri D, Di Paola R, Navarra M, Cuzzocrea S, Esposito E. A new coultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflammation. 2013;10:91. doi:10.1186/1742-2094-10-91.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun. 2011;25:1099–112. doi:10.1016/j.bbi.2011.02.006.View ArticlePubMedGoogle Scholar


© The Author(s). 2016